Axogen Inc (AXGN) - Net Assets
Based on the latest financial reports, Axogen Inc (AXGN) has net assets worth $244.81 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($289.49 Million) and total liabilities ($44.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AXGN tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $244.81 Million |
| % of Total Assets | 84.57% |
| Annual Growth Rate | 8.47% |
| 5-Year Change | 14.48% |
| 10-Year Change | 763.52% |
| Growth Volatility | 1498.4 |
Axogen Inc - Net Assets Trend (1986–2025)
This chart illustrates how Axogen Inc's net assets have evolved over time, based on quarterly financial data. See AXGN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Axogen Inc (1986–2025)
The table below shows the annual net assets of Axogen Inc from 1986 to 2025. For live valuation and market cap data, see AXGN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $128.85 Million | +24.00% |
| 2024-12-31 | $103.91 Million | +8.62% |
| 2023-12-31 | $95.67 Million | -5.28% |
| 2022-12-31 | $101.00 Million | -10.26% |
| 2021-12-31 | $112.55 Million | -8.61% |
| 2020-12-31 | $123.15 Million | -6.81% |
| 2019-12-31 | $132.15 Million | -10.09% |
| 2018-12-31 | $146.98 Million | +483.68% |
| 2017-12-31 | $25.18 Million | +68.77% |
| 2016-12-31 | $14.92 Million | +82.06% |
| 2015-12-31 | $8.20 Million | +172.88% |
| 2014-12-31 | $-11.25 Million | -8330.57% |
| 2013-12-31 | $136.63K | +104.83% |
| 2012-12-31 | $-2.83 Million | -146.60% |
| 2011-12-31 | $6.07 Million | -39.46% |
| 2010-12-31 | $10.03 Million | -9.33% |
| 2009-12-31 | $11.06 Million | +3431.81% |
| 2008-12-31 | $313.19K | -65.16% |
| 2007-12-31 | $898.82K | -30.69% |
| 2006-12-31 | $1.30 Million | -22.07% |
| 2005-12-31 | $1.66 Million | -27.09% |
| 2004-12-31 | $2.28 Million | +1584.11% |
| 2003-12-31 | $-153.77K | -115.90% |
| 2002-12-31 | $966.80K | -72.69% |
| 2001-12-31 | $3.54 Million | -24.99% |
| 2000-12-31 | $4.72 Million | -22.63% |
| 1999-12-31 | $6.10 Million | -27.38% |
| 1998-12-31 | $8.40 Million | -4.55% |
| 1997-12-31 | $8.80 Million | -19.27% |
| 1996-12-31 | $10.90 Million | -2.68% |
| 1995-12-31 | $11.20 Million | 0.00% |
| 1994-12-31 | $11.20 Million | +1.82% |
| 1993-12-31 | $11.00 Million | +6.80% |
| 1992-12-31 | $10.30 Million | +6.19% |
| 1991-12-31 | $9.70 Million | +10.23% |
| 1990-12-31 | $8.80 Million | +27.54% |
| 1989-12-31 | $6.90 Million | +4.55% |
| 1988-12-31 | $6.60 Million | +13.79% |
| 1987-12-31 | $5.80 Million | +7.41% |
| 1986-12-31 | $5.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23712.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $472.00K | 0.37% |
| Other Components | $435.34 Million | 337.87% |
| Total Equity | $128.85 Million | 100.00% |
Axogen Inc Competitors by Market Cap
The table below lists competitors of Axogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Expressway Co Ltd
SHG:600548
|
$2.25 Billion |
|
LCI Industries
NYSE:LCII
|
$2.25 Billion |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
$2.25 Billion |
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
$2.25 Billion |
|
Prestige Brand Holdings Inc
NYSE:PBH
|
$2.25 Billion |
|
BitVentures Limited
NASDAQ:BVC
|
$2.25 Billion |
|
Greatek Electronics Inc
TW:2441
|
$2.25 Billion |
|
Elkem ASA
OL:ELK
|
$2.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 103,907,000 to 128,847,000, a change of 24,940,000 (24.0%).
- Net loss of 15,703,000 reduced equity.
- Other factors increased equity by 40,643,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.70 Million | -12.19% |
| Other Changes | $40.64 Million | +31.54% |
| Total Change | $- | 24.00% |
Book Value vs Market Value Analysis
This analysis compares Axogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.33x to 15.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-12-31 | $1.94 | $43.40 | x |
| 1987-12-31 | $1.68 | $43.40 | x |
| 1988-12-31 | $1.87 | $43.40 | x |
| 1989-12-31 | $1.90 | $43.40 | x |
| 1990-12-31 | $2.44 | $43.40 | x |
| 1991-12-31 | $2.52 | $43.40 | x |
| 1992-12-31 | $2.94 | $43.40 | x |
| 1993-12-31 | $3.12 | $43.40 | x |
| 1994-12-31 | $2.93 | $43.40 | x |
| 1995-12-31 | $2.93 | $43.40 | x |
| 1996-12-31 | $2.87 | $43.40 | x |
| 1997-12-31 | $2.28 | $43.40 | x |
| 1998-12-31 | $2.10 | $43.40 | x |
| 1999-12-31 | $1.54 | $43.40 | x |
| 2000-12-31 | $1.21 | $43.40 | x |
| 2001-12-31 | $0.90 | $43.40 | x |
| 2002-12-31 | $0.24 | $43.40 | x |
| 2003-12-31 | $-0.04 | $43.40 | x |
| 2004-12-31 | $0.55 | $43.40 | x |
| 2005-12-31 | $0.40 | $43.40 | x |
| 2006-12-31 | $0.31 | $43.40 | x |
| 2007-12-31 | $0.22 | $43.40 | x |
| 2008-12-31 | $0.07 | $43.40 | x |
| 2009-12-31 | $2.57 | $43.40 | x |
| 2010-12-31 | $2.33 | $43.40 | x |
| 2011-12-31 | $1.64 | $43.40 | x |
| 2012-12-31 | $-0.26 | $43.40 | x |
| 2013-12-31 | $0.01 | $43.40 | x |
| 2014-12-31 | $-0.63 | $43.40 | x |
| 2015-12-31 | $0.31 | $43.40 | x |
| 2016-12-31 | $0.49 | $43.40 | x |
| 2017-12-31 | $0.76 | $43.40 | x |
| 2018-12-31 | $3.96 | $43.40 | x |
| 2019-12-31 | $3.37 | $43.40 | x |
| 2020-12-31 | $3.08 | $43.40 | x |
| 2021-12-31 | $2.73 | $43.40 | x |
| 2022-12-31 | $2.40 | $43.40 | x |
| 2023-12-31 | $2.23 | $43.40 | x |
| 2024-12-31 | $2.35 | $43.40 | x |
| 2025-12-31 | $2.80 | $43.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.97%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.72x
- Recent ROE (-12.19%) is above the historical average (-294.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 9.26% | 10.64% | 0.70x | 1.24x | $-40.00K |
| 1987 | 15.52% | 15.52% | 0.84x | 1.19x | $320.00K |
| 1988 | 9.09% | 9.38% | 0.11x | 8.82x | $-60.00K |
| 1989 | 5.80% | 5.88% | 0.81x | 1.22x | $-290.00K |
| 1990 | 10.23% | 11.25% | 0.84x | 1.08x | $20.00K |
| 1991 | 10.31% | 12.35% | 0.78x | 1.07x | $30.00K |
| 1992 | 6.80% | 7.61% | 0.84x | 1.07x | $-330.00K |
| 1993 | 5.45% | 5.61% | 0.84x | 1.15x | $-500.00K |
| 1994 | 1.79% | 1.42% | 1.11x | 1.13x | $-920.00K |
| 1995 | 1.79% | 1.42% | 1.11x | 1.13x | $-920.00K |
| 1996 | -5.50% | -4.58% | 1.07x | 1.13x | $-1.69 Million |
| 1997 | -26.14% | -18.70% | 1.04x | 1.34x | $-3.18 Million |
| 1998 | -4.76% | -3.10% | 1.22x | 1.26x | $-1.24 Million |
| 1999 | -27.87% | -13.82% | 1.40x | 1.44x | $-2.31 Million |
| 2000 | -60.58% | -19.59% | 1.72x | 1.80x | $-3.33 Million |
| 2001 | 37.95% | 8.43% | 2.51x | 1.79x | $989.47K |
| 2002 | -269.22% | -37.99% | 1.65x | 4.29x | $-2.70 Million |
| 2003 | 0.00% | -17.71% | 2.69x | 0.00x | $-1.27 Million |
| 2004 | 100.64% | 215.65% | 0.38x | 1.23x | $2.07 Million |
| 2005 | -31.89% | -119.68% | 0.24x | 1.10x | $-697.01K |
| 2006 | -28.31% | -289.90% | 0.08x | 1.17x | $-496.86K |
| 2007 | -83.33% | -745.77% | 0.09x | 1.22x | $-838.86K |
| 2008 | -332.30% | -1431.30% | 0.14x | 1.67x | $-1.07 Million |
| 2009 | 136.03% | 60.40% | 1.48x | 1.52x | $13.94 Million |
| 2010 | -13.12% | -1442.16% | 0.01x | 1.01x | $-2.32 Million |
| 2011 | -151.84% | -190.11% | 0.39x | 2.06x | $-9.83 Million |
| 2012 | 0.00% | -122.44% | 0.38x | 0.00x | $-9.14 Million |
| 2013 | -10654.00% | -132.97% | 0.40x | 202.62x | $-14.57 Million |
| 2014 | 0.00% | -105.31% | 1.03x | 0.00x | $-16.59 Million |
| 2015 | -162.97% | -48.87% | 0.73x | 4.58x | $-14.18 Million |
| 2016 | -96.58% | -35.06% | 0.89x | 3.11x | $-15.90 Million |
| 2017 | -41.48% | -17.29% | 1.03x | 2.34x | $-12.96 Million |
| 2018 | -15.24% | -26.68% | 0.52x | 1.09x | $-37.10 Million |
| 2019 | -22.04% | -27.29% | 0.69x | 1.17x | $-42.34 Million |
| 2020 | -19.31% | -21.18% | 0.56x | 1.64x | $-36.10 Million |
| 2021 | -23.98% | -21.19% | 0.61x | 1.85x | $-38.24 Million |
| 2022 | -28.66% | -20.89% | 0.71x | 1.93x | $-39.05 Million |
| 2023 | -22.70% | -13.66% | 0.81x | 2.06x | $-31.28 Million |
| 2024 | -9.59% | -5.32% | 0.92x | 1.96x | $-20.35 Million |
| 2025 | -12.19% | -6.97% | 1.02x | 1.72x | $-28.59 Million |
Industry Comparison
This section compares Axogen Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $255,652,955
- Average return on equity (ROE) among peers: -95.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axogen Inc (AXGN) | $244.81 Million | 9.26% | 0.18x | $2.25 Billion |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $157.58 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $15.78 Million |
| Aethlon Medical Inc (AEMD) | $5.77 Million | -211.71% | 0.43x | $2.54 Million |
| Acutus Medical Inc (AFIB) | $-225.81 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.37 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $5.95 Million |
| Allurion Technologies, Inc. (ALUR) | $-32.31 Million | 0.00% | 0.00x | $6.94 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $4.52 Million |
| Artivion Inc (AORT) | $62.63 Million | 11.50% | 0.48x | $1.04 Billion |
| Apyx Medical Inc (APYX) | $22.12 Million | 0.49% | 0.28x | $173.78 Million |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed periphera… Read more